Galectin-3’s Complex Interactions in Pancreatic Ductal Adenocarcinoma: From Cellular Signaling to Therapeutic Potential-Reference-Cited by-同舟云学术

Galectin-3’s Complex Interactions in Pancreatic Ductal Adenocarcinoma: From Cellular Signaling to Therapeutic Potential

Published:2023-10-10 Issue:10 Volume:13 Page:1500
ISSN:2218-273X
Container-title:Biomolecules
language:en
Short-container-title:Biomolecules

Author:

Dimitrijevic Stojanovic Milica¹²,Stojanovic Bojan³^ORCID,Radosavljevic Ivan³,Kovacevic Vojin³,Jovanovic Ivan²^ORCID,Stojanovic Bojana S.²⁴,Prodanovic Nikola³^ORCID,Stankovic Vesna¹,Jocic Miodrag⁵^ORCID,Jovanovic Marina⁶

Affiliation:

1. Department of Pathology, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia

2. Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia

3. Department of Surgery, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia

4. Department of Pathophysiology, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia

5. Institute for Transfusiology and Haemobiology, Military Medical Academy, 11000 Belgrade, Serbia

6. Department of Internal Medicine, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia

Abstract

Galectin-3 (Gal-3) plays a multifaceted role in the development, progression, and prognosis of pancreatic ductal adenocarcinoma (PDAC). This review offers a comprehensive examination of its expression in PDAC, its interaction with various immune cells, signaling pathways, effects on apoptosis, and therapeutic resistance. Additionally, the prognostic significance of serum levels of Gal-3 is discussed, providing insights into its potential utilization as a biomarker. Critical analysis is also extended to the inhibitors of Gal-3 and their potential therapeutic applications in PDAC, offering new avenues for targeted treatments. The intricate nature of Gal-3’s role in PDAC reveals a complex landscape that demands a nuanced understanding for potential therapeutic interventions and monitoring.

Funder

Faculty of Medical Sciences at the University of Kragujevac, Serbia

Ministry of Science, Technological Development, and Innovation of the Republic of Serbia

Publisher

MDPI AG

Subject

Molecular Biology,Biochemistry

Link

https://www.mdpi.com/2218-273X/13/10/1500/pdf

Reference81 articles.

1. Adamska, A., Domenichini, A., and Falasca, M. (2017). Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies. Int. J. Mol. Sci., 18.

2. Pancreatic ductal adenocarcinoma: Biological hallmarks, current status, and future perspectives of combined modality treatment approaches;Orth;Radiat. Oncol.,2019

3. Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy;Sarantis;World J. Gastrointest. Oncol.,2020

4. Michalak, N., and Małecka-Wojciesko, E. (2023). Modifiable Pancreatic Ductal Adenocarcinoma (PDAC) Risk Factors. J. Clin. Med., 12.

5. Pancreatic cancer stromal biology and therapy;Xie;Genes. Dis.,2015

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glycosylation in the tumor immune response: the bitter side of sweetness;Acta Biochimica et Biophysica Sinica;2024-06-28

2. Redefining Immune Dynamics in Acute Pancreatitis: The Protective Role of Galectin-3 Deletion and Treg Cell Enhancement;Biomolecules;2024-05-30

3. Galectin-1 in Pancreatic Ductal Adenocarcinoma: Bridging Tumor Biology, Immune Evasion, and Therapeutic Opportunities;International Journal of Molecular Sciences;2023-10-24